Core Viewpoint - The company has announced the repurchase and cancellation of certain restricted stocks and stock options due to the departure of specific incentive targets, which will not significantly impact its financial status or operational results [21][22][27]. Group 1: Repurchase and Cancellation Details - The total number of restricted stocks to be repurchased and canceled is 346,000 shares, which includes 196,000 shares from the 2024 incentive plan and 150,000 shares from the 2025 incentive plan [2][26]. - The repurchase price for the 2024 incentive plan is set at 3.97 yuan per share, while the price for the 2025 incentive plan is 4.11 yuan per share [2][18]. - A total of 271,000 stock options will be canceled, comprising 196,000 from the 2024 plan and 75,000 from the 2025 plan [2][26]. Group 2: Approval Procedures - The company’s board of directors approved the repurchase and cancellation plan during the 33rd meeting on November 28, 2025, following the necessary authorizations from previous shareholder meetings [3][10]. - The relevant approval procedures for both the 2024 and 2025 incentive plans have been duly followed, including board meetings and public disclosures [4][11]. Group 3: Impact on Share Structure - Following the completion of the repurchase and cancellation, the company's total shares will decrease by 346,000, resulting in a new total of 928,512,628 shares [20][27]. - The repurchase will not lead to any changes in the controlling shareholder or actual controller of the company, maintaining compliance with listing conditions [20][21]. Group 4: Financial Implications - The repurchase and cancellation actions are in accordance with the relevant regulations and will not have a substantial impact on the company's financial condition or operational results [21][22]. - The funds for the repurchase will come from the company's own resources, amounting to 778,120 yuan for the 2024 plan and 616,500 yuan for the 2025 plan [16][19].

Core Viewpoint - The company, Sichuan Kelun Pharmaceutical Co., Ltd., has disclosed its third-quarter report for 2025, ensuring the accuracy and completeness of the information provided [7][8]. Financial Data - The third-quarter financial report has not been audited [6]. - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Board Meeting Resolutions - The eighth board of directors held its ninth meeting on October 29, 2025, where all nine directors were present, and the meeting complied with legal and regulatory requirements [7][8]. - The board unanimously approved the third-quarter report with a vote of 9 in favor, 0 against, and 0 abstentions [8]. - Several internal management systems were revised and approved, including the internal audit system, information disclosure management system, and ESG management system, all receiving unanimous approval [10][12][14]. Important Matters - The company has made revisions to multiple internal management systems, including the anti-fraud system, external guarantee management system, and major event reporting system, with all revisions approved unanimously [19][20][21]. - The company has also updated its investor relations management system and securities investment management system, ensuring compliance with relevant laws and regulations [27][28]. Disclosure and Compliance - The company emphasizes the importance of accurate and complete information disclosure, with all board members bearing legal responsibility for the report's content [2][7]. - The revised internal systems and procedures will be published on the designated information disclosure website [11][31].